CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 59 enrolled
Drug / intervention
LY2541546 - SC +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01742091
NCT01742091Phase 1Completed
CompareCT.gov

A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women

Eli Lilly and Company·interventional·Posted Dec 5, 2012·Updated Jul 18, 2018

In Brief

A Phase 1 clinical trial evaluating LY2541546 - SC, LY2541546 - IV, and 2 other interventions for Healthy. Completed, enrolled 59 participants across 5 sites.

Detailed Summary

The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes the body to get rid of it, the overall effect of the study drug on the body, and whether antibodies to the study drug are formed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2012
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.6 years ago

Interventions

LY2541546 - SCdrug

Administered SC

LY2541546 - IVdrug

Administered IV

Placebo - SCdrug

Administered SC

Placebo - IVdrug

Administered IV